Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Inclusion Criteria: * Ability to provide written informed consent * Men or women 18 years of age or older * Current diagnosis of a recurrence of non-severe, non-complicated CDI * Subject has a clinical response to standard-of-care CDI antibiotics for the most recent CDI episode Exclusion Criteria: * Pregnant, breast-feeding, or considering becoming pregnant during the study * Prior history, evidence, or diagnosis of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) * Any prior diagnosis of diarrhea-predominant irritable bowel syndrome * Systemic chemotherapy or radiation for the treatment of cancer during the 60 days prior to consent or planned during the 8 weeks following Randomization * Prior fecal transplant for any condition, regardless of route of administration in the last year or plans to undergo during the study * Major intra-abdominal surgery within the past 60 days prior to Screening * History of total colectomy/ileostomy or bariatric surgery * Admitted to, or expected to be admitted to an intensive care unit for any medical reason. Note: Residents of long term care facilities are eligible study entry * Planned hospitalization or invasive surgery during the study * Severe acute illness unrelated to CDI